ScripMerck KGaA has broken its silence regarding rumors of a takeover bid for SpringWorks Therapeutics and stated that talks to buy the US-based cancer and rare disease specialist are well advanced. Reacti
ScripAt a time when accessing capital has become increasingly difficult, leaving more and more biopharma firms to consider a range of less-than-stellar strategic alternatives, Alis Biosciences has emerged
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Daiichi Sankyo Tries Wayfinder’s
Pink SheetThe UK’s originator drugs and generics industries are at odds over a rise in the clawbacks that companies must pay the government on the sales of branded medicines to the National Health Service under